Phospholipase a2 expression and activity and use thereof for...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/46 (2006.01) A61K 31/20 (2006.01) A61K 38/17 (2006.01) A61P 9/00 (2006.01) A61P 25/28 (2006.01) A61P 29/00 (2006.01) C12N 15/55 (2006.01) C12Q 1/34 (2006.01) C12Q 1/44 (2006.01) G01N 33/68 (2006.01)

Patent

CA 2388659

The present invention provides methods of preventing and treating neural inflammatory or demyelinating disease, such as multiple sclerosis, via an inhibition of the activity or expression of phospholipase A2. The invention further relates to methods of identifying phospholipase A2 inhibitors and their use thereof for the prevention and/or treatment of neural inflammatory or demyelinating disease. An observed increase in the amount of phospholipase A2 in neural lesions in the EAE animal model system indicates that elevated phospholipase A2 activity or levels correlate with neural inflammatory or demyelinating disease. Therefore, in a further aspect the invention provides methods for the diagnosis and prognostication of neural inflammatory or demyelinating disease, such as multiple sclerosis.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Phospholipase a2 expression and activity and use thereof for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phospholipase a2 expression and activity and use thereof for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phospholipase a2 expression and activity and use thereof for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1874810

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.